IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Czech National Bank

Czech National Bank grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 35,279 shares of the medical research company’s stock after buying an additional 559 shares during the period. Czech National Bank’s holdings in IQVIA were worth $8,360,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC acquired a new position in IQVIA in the 1st quarter valued at $31,000. Versant Capital Management Inc grew its position in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Riverview Trust Co acquired a new position in IQVIA in the first quarter valued at $32,000. Opal Wealth Advisors LLC purchased a new position in IQVIA during the second quarter worth about $27,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the second quarter worth approximately $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Morgan Stanley boosted their price target on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Robert W. Baird boosted their target price on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. JPMorgan Chase & Co. raised their price target on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Finally, Evercore ISI increased their price objective on shares of IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $267.00.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Performance

Shares of IQV opened at $229.84 on Friday. The firm has a market cap of $41.90 billion, a price-to-earnings ratio of 31.40, a PEG ratio of 2.18 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The business’s 50 day moving average is $240.74 and its two-hundred day moving average is $232.55. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.22 earnings per share. Analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.